The thesis

DexCom sells continuous glucose monitoring systems and grows revenue 11.2% year over year at a 19.4% net margin. Analysts rate the stock a buy and it trades at 31.3 times earnings. Our conviction signal is dormant at 23 out of 100, so the model finds no active edge here. The tension is real: GLP-1 adoption expands metabolic monitoring demand but may shrink the insulin-dependent user base that drives device volume. The bull case prices the expansion; the risk case prices the erosion; the score prices neither.

Why now

A risk-on rotation after the election-driven market surge lifts growth healthcare names, yet DexCom's signal stays inactive. That gap between a friendly macro tape and a dormant conviction score is the moment to check whether the GLP-1 mix is accretive or dilutive to device demand.

What to watch

Quarterly revenue growth against the 11.2% baseline and any management commentary on GLP-1 user attachment rates. Watch gross margin versus 63.4% and international CGM volume trends over the next one to three quarters for the direction of the metabolic mix.

Key risks

At 31.3 times earnings on 11.2% growth, the multiple assumes acceleration that GLP-1-driven insulin reduction could deny. If GLP-1 users skip or delay CGM adoption, revenue growth decelerates into a de-rating. A 63.4% gross margin also leaves room for competitive pricing pressure to compress profitability.

Theme exposure